ArticleJournal of clinical medicine2019
Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- A systematic review and meta-analysis of the diagnosis and surgical management of carcinoid heart disease.Frontiers in cardiovascular medicine · 2024Pooled it
- Article
- Multivalvular Carcinoid Heart Disease: The Role of Echocardiography in Diagnosis and Selection for Heterotopic Bicaval Valve Implantation.Diagnostics (Basel, Switzerland) · 2026Article
- Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.Cardio-oncology (London, England) · 2026Article
- Transcatheter Valve Replacement in Carcinoid Heart Disease: A Potential Change of Paradigm.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Article
- Carcinoid Heart Disease.Journal of the advanced practitioner in oncology · 2024Article
- Managing end-stage carcinoid heart disease: A case report and literature review.World journal of gastrointestinal oncology · 2024Article
- Late-stage diagnosis of carcinoid heart disease due to lack of access to health care.Cardio-oncology (London, England) · 2023Article
- Analysis of Patients with NET G1/G2 Neuroendocrine Tumors of the Small Intestine in the Course of Carcinoid Heart Disease-A Retrospective Study.Journal of clinical medicine · 2023Article
- Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador.Healthcare (Basel, Switzerland) · 2022Article
- European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease.Journal of neuroendocrinology · 2022Article
- Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study.Cancers · 2022Article
- Prognostic value of prognostic nutritional index and its variations in advanced non-small-cell lung cancer patients treated with anlotinib monotherapy.Journal of clinical laboratory analysis · 2022Article
- Health resource utilisation by patients with neuroendocrine tumours with or without carcinoid heart disease: a multinational study.Ecancermedicalscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The background to this study was that factors associated with carcinoid heart disease (CHD) and its impacts on overall survival (OS) are scantly investigated in patients (pts) with neuroendocrine tumors (NETs). In terms of materials and methods, a retrospective multicenter cohort study was conducted of factors associated with CHD in advanced NET pts with carcinoid syndrome (CS) and/or elevated urinary 5-hidroxyindole acetic acid (u5HIAA). CHD was defined as at least moderate right valve alterations. The results were the following: Among the 139 subjects included, the majority had a midgut NET (54.2%), 81.3% had CS, and 93% received somatostatin analogues. In a median follow-up of 39 months, 48 (34.5%) pts developed CHD, with a higher frequency in pts treated in public (77.2%) versus private settings (22.9%). In a multivariate logistic regression, unknown primary or colorectal NETs (Odds Ratio (OR) 4.35;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.